Zidovudine

Human medicines European public assessment report (EPAR): Ziagen, abacavir, Date of authorisation: 08/07/1999, Revision: 48, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, HIV, Diarrhea, Marketing, Zidovudine, Lethargy, Agency, INN, Risk, Immune system, Fever, Fatigue, ATC, AIDS, International, Cough, HLA, Headache, CD4, Ageing, Nausea, Blood, Somatic symptom disorder, Profile, Rash, Language, Liver, Allergy, Hypersensitivity, European Medicines Agency, Infection, Tablet, Myalgia, Select, Cell, Human, Lamivudine, NRTI, Anatomy, Vomiting, IIA, Periodic breathing, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Ziagen, abacavir, Date of authorisation: 08/07/1999, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ziagen, abacavir, Date of authorisation: 08/07/1999, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Peripheral neuropathy, Diarrhea, Marketing, Zidovudine, European Commission, Protease, Pharyngitis, INN, Immune system, Heartburn, HIV/AIDS, Fatigue, Saquinavir, Darunavir, ATC, Depression, Itch, Ritonavir, AIDS, International, Capsule, Cough, European, Headache, Disease, CD4, Ageing, Body surface area, Blood, Sore throat, Nausea, Rash, Language, Mouth, Abdominal pain, Dizziness, Flushing, Infection, Food, Indigestion, HIV, Tablet, Chronic pain, Reproduction, Back pain, Select, Committee, Patient, Dysgeusia, Risk management, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Lopinavir, CHMP, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 - Featuring Amgen, Biocon, Dr. Reddy's Laboratories and Intas Pharmaceuticals Among Others

Retrieved on: 
Saturday, January 21, 2023
Premature, Kidney disease, Laboratory, AKI, Stroke, EPO, DNA, Johnson & Johnson, Acute kidney injury, CKD, Heart failure, SCI, EOP, COVID-19, Ageing, Cancer, Zidovudine, Red blood cell, Anemia, Intas Pharmaceuticals, Chronic kidney disease, Diabetes, Patient, LG Chem, Risk, RBC, MI, Amgen, Pfizer, HIV, Depression, Fine chemical, Semiconductor, Vaccine, Medical device, Pharmaceutical industry, Potash, Growth

The "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 13.8 Billion by 2027, exhibiting a CAGR of 5.87% during 2021-2027.
  • What is the structure of the global erythropoietin drugs market and who are the key players?

Global Erythropoietin Drugs Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Health, Pharmaceutical, ESAS, Premature, Anemia, Ageing, AKI, COVID-19, Zidovudine, HIV, Depression, DNA, Risk, SCI, Chronic kidney disease, Red blood cell, EOP, Growth, CKD, Patient, Diabetes, Heart failure, MI, Cancer, Stroke, Acute kidney injury, EPO, RBC, Pharmaceutical industry, Vaccine, Medical device

These insights are included in the report as a major market contributor.

Key Points: 
  • These insights are included in the report as a major market contributor.
  • Erythropoietin (EPO) is a hormone produced by kidneys to stimulate the production of red blood cells (RBCs).
  • The publisher provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2022-2027.
  • Our report has categorized the market based on drug class, product type, application and end user.

Global Anemia And Other Blood Disorder Drugs Markets, 2016-2021, 2021-2026F, 2031F by Type, Distribution Channel, Route of Administration, Anemia Type - ResearchAndMarkets.com

Retrieved on: 
Friday, July 29, 2022
General Health, Pharmaceutical, Health, Other Health, Degenerative disease, Mitigation, Normal, Safety, Aplastic anemia, Country, Market share, High, GlaxoSmithKline, Microcytic, Hoffmann-La Roche, Anemia, Zidovudine, World Bank, Knowledge, Macrocytic anemia, World, Human, Woman, Hospira, Novartis, Epoetin alfa, Technology, Growth, Amgen, HIV, Prevalence, Route of administration, Chronic kidney disease, Pharmacy, Pfizer, Disease, FDA, Blood, REMS, Anti-transglutaminase antibodies, Organic acid, Bayer, Janssen Pharmaceuticals, Hospital, HIV/AIDS, Therapy, Administration, Patient, Macrocytic, Animal, Dietary supplement, Pharmaceutical industry, Lithium, Pyridoxine, Erythropoietin, Deferoxamine

The anemia and other blood disorder drugs market consists of sales of anemia and other blood disorder drugs and related services.

Key Points: 
  • The anemia and other blood disorder drugs market consists of sales of anemia and other blood disorder drugs and related services.
  • The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia and aplastic anemia.
  • Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.4.
  • Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Anemia Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    7.1.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points: 
  • If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
  • Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
  • Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
  • Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

Penn Dental Medicine Study Shows How HIV Infection Impacts Brain's White Matter

Retrieved on: 
Friday, June 18, 2021
Hepatotoxins, Medical specialties, Prevention of HIV/AIDS, Retroviridae, Health, HIV/AIDS, Pandemics, HIV, Oligodendrocyte, Zidovudine, HIV-associated neurocognitive disorder

PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.

Key Points: 
  • PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.
  • Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)the lifesaving drugs that many with HIV use dailycan reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
  • In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production.
  • "Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto , professor at Penn Dental Medicine and the study's co-senior author.

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Retrieved on: 
Tuesday, June 8, 2021
Hepatotoxins, Chemical substances, Medical specialties, Chemical compounds, Management of HIV/AIDS, Zidovudine, Reverse-transcriptase inhibitor, HIV, Integrase inhibitor, Rilpivirine, Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.

Key Points: 
  • The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
  • Integrase inhibitors, in addition to capsid inhibitors and nucleoside reverse transcriptase inhibitors, are a class of agents under investigation as long-acting antiretroviral therapies.
  • Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention.
  • Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiretroviral therapeutics.

AHF: Lessons from 40 Years of AIDS, ‘The Other Pandemic,’ Must Guide Global Response to COVID-19

Retrieved on: 
Friday, June 4, 2021
White House, Federal Government, AIDS, Public policy, Government, Health, Healthcare reform, Public policy, Infectious diseases, Medical specialties, Health, Azides, Hepatotoxins, Zidovudine, HIV/AIDS, Chemical substances, AIDS Healthcare Foundation

Forty years of painful lessons from AIDS offer applicable lessons for our global fight against COVID-19, lessons that should not be ignored, said Michael Weinstein, president of AHF.

Key Points: 
  • Forty years of painful lessons from AIDS offer applicable lessons for our global fight against COVID-19, lessons that should not be ignored, said Michael Weinstein, president of AHF.
  • For years we have needed to radically overhaul and change the architecture of our global public health system and its structures.
  • Thankfully, the 1996 introduction of lifesaving combined drug antiretroviral therapies (ART)the so-called AIDS drug cocktail saved countless millions from death.
  • However, HIV/AIDS remains a deadly global health issue, taking the lives of nearly 700,000 people annually around the world.

Global HIV Pre-Exposure Prophylaxis (HIV PrEP) Disease Analysis Report 2021: Uptake of PrEP is Expected to Continue Following Positive European Reimbursement Decisions - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, Pharmaceutical, Hepatotoxins, Medicine, Clinical medicine, Prevention of HIV/AIDS, HIV/AIDS, Pre-exposure prophylaxis, Emtricitabine/tenofovir, Management of HIV/AIDS, Prep, Neutralizing antibody, Zidovudine

The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.
  • However, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as Gilead's marketing efforts.
  • Within the EU and UK, Truvada is the only approved agent for PrEP but generates minimal sales due to generic competition since July 2017.
  • There are currently six agents in clinical development for pharmacological PrEP, comprising five antiretrovirals and a single broadly neutralizing antibody.